Novo Nordisk has sought approval of oral version of Wegovy – report

Posted on by wpadmin
Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024

Victor Golmer

  • Novo Nordisk (NVO) earlier this year submitted an application to the U.S. FDA seeking approval of an oral version of its blockbuster GLP-1 weight loss medicine Wegovy (semaglutide).
  • A company spokesperson confirmed the filing to BioPharma Dive.
  • Novo Nordisk reported

Leave a Reply

Your email address will not be published. Required fields are marked *